Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

15.95
-0.1300-0.81%
Post-market: 16.951.00+6.27%17:36 EST
Volume:283.98K
Turnover:4.50M
Market Cap:2.05B
PE:-18.85
High:16.07
Open:15.74
Low:15.55
Close:16.08
52wk High:21.50
52wk Low:9.61
Shares:128.30M
Float Shares:78.65M
Volume Ratio:1.49
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8460
EPS(LYR):-0.8457
ROE:-18.95%
ROA:-5.37%
PB:3.43
PE(LYR):-18.86

Loading ...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)

TIPRANKS
·
Jan 30

Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%

MT Newswires Live
·
Jan 29

Ryoncil® Net Revenues Increase for the Quarter to US$30M

GlobeNewswire
·
Jan 29

Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting

MT Newswires Live
·
Jan 27

Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands

TIPRANKS
·
Jan 27

BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd

Reuters
·
Jan 27

Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd

THOMSON REUTERS
·
Jan 27

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

GlobeNewswire
·
Jan 27

JPMorgan Ceases to Be Substantial Holder in Mesoblast

TIPRANKS
·
Jan 27

Mesoblast Wins FDA Backing on Pain and Opioid-Reduction Data for Rexlemestrocel-L in Chronic Low Back Pain

TIPRANKS
·
Jan 21

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain

Benzinga_recent_news
·
Jan 21

FDA Feedback Boosts Mesoblast’s Rexlemestrocel‑L Bid in Chronic Low Back Pain

TIPRANKS
·
Jan 19

BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L

Reuters
·
Jan 19

Mesoblast Ltd - Rexlemestrocel-L Receives Rmat Designation From FDA

THOMSON REUTERS
·
Jan 19

Mesoblast Ltd - Significant Pain Reduction and Opioid Cessation in Phase 3 Trial

THOMSON REUTERS
·
Jan 19

Mesoblast Ltd - Second Phase 3 Trial Msb-DR004 Over 50% Enrolled

THOMSON REUTERS
·
Jan 19

Mesoblast Trims Option Overhang After Late-2025 Lapse of 1.45 Million Unquoted Options

TIPRANKS
·
Jan 16

Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies

MT Newswires Live
·
Jan 14

Mesoblast Issues 6.9 Million New Shares Following Conversion of Unquoted Securities

TIPRANKS
·
Jan 13

Mesoblast Seeks ASX Quotation for 7.3 Million New Shares from Employee Scheme

TIPRANKS
·
Jan 13